Document text
Principal Investigator: Alex Joseph Guseman
Organization: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Fiscal Year: 2022
Award: $100,000
Funding agency: National Institute of General Medical Sciences
Project Summary/Abstract
In late 2019, the SARS-CoV2 virus emerged as a global pandemic, causing the severe respiratory disease
COVID-19 and resulting in millions of deaths worldwide. As a coronavirus, SARS-CoV2 host interactions are
dictated through the Spike proteins that encompass the virion. The Spike protein of SARS-CoV2, is a highly
glycosylated trimer that interacts with the ACE2 receptor on host cells via the receptor binding domain (RBD)
to facilitate viral entry. As a key player in viral infection, the Spike trimer, and the RBD, have become the target
for a majority of approved therapeutics and vaccines used to treat or prevent SARS-CoV2. In this proposal, the
PI uses a novel antiviral lectin, BOA, which he has demonstrated that BOA binds glycans on the spike protein,
and inhibits SARS-CoV2 viral entry. To understand how BOA inhibits viral entry, during the K99 phase of the
award, the PI will determine the mechanism by which BOA inhibits in SARS-CoV2 viral infection using a
combination of viral inhibition assays, biophysical assays, and electron microscopy. Subsequently the PI will
test the ability of BOA to inhibit emerging SARS-CoV2 variants of concern that have accumulated mutations to
various regions of the spike protein that facilitate immune escape. Expanding upon these findings during the
independent R00 phase of this award, the PI will use skills developed during the K99 phase to establish his
own independent research group, where they will test the ability of the BOA lectin to inhibit viral entry of Beta-
Coronaviruses known to infect humans. Successful completion of these aims could provide a bona fide broad
spectrum coronavirus inhibitor to be further developed as a therapeutic or diagnostic for the next coronavirus
that emerges. The proposed research, will provide the PI with new and exciting training in virology as well as
electron microscopy which he intends to pass on to his future trainees. The proposed work will be completed at
The University of Pittsburgh, where the Department of Structural Biology and Center for Vaccine Research will
provide unmatched access to resources, instrumentation, and experts in the field. The PI has assembled an
exciting mentorship team of virologists and biophysicists who he will meet with monthly to receive advice,
discuss results, designed new experiments, and prepare for transitioning into an independent career. To aide
in his career development, the university offers numerous workshops to develop skills such as grant writing
and mentorship. The PI will also attend conferences to give presentations and hone his science
communications skills. In Summary, the proposed training and career development plans will prepare the PI to
lead his own independent research group and become a leader in his field.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Animal Model><Animal Models and Related Studies><Antibodies><Assay><Award><Binding><Bioassay><Biochemical><Biologic Assays><Biological Assay><Biophysics><Burkholderia><COVID-19><COVID-19 S protein><COVID-19 infection><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 infection><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cell Body><Cells><Cessation of life><Clinic><CoV S protein><CoV emergence><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><CoV-2><CoV2><Communication><Coronaviridae><Coronavirus><Coronavirus glycoprotein S><Coronavirus spike protein><D-Mannose><Dangerousness><Data><Death><Development><Development Plans><Diagnostic><Disease><Disorder><Educational workshop><Electron Microscopy><FDA EUA><FDA Emergency Use Authorization><Family><Food and Drug Administration EUA><Food and Drug Administration Emergency Use Authorization><Future><Genetic Alteration><Genetic Change><Genetic defect><Glycans><Glycoproteins><Grant><HCoV><HIV><Health><Health Care Providers><Health Personnel><Healthcare Providers><Healthcare worker><Human><Human Immunodeficiency Viruses><Immune><Immunes><Incentives><Infection><Intervention><Intervention Strategies><Knowledge><LAV-HTLV-III><Lead><Lectin><Left><Lilium><Lily><Link><Lymphadenopathy-Associated Virus><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Mannopyranose><Mannopyranoside><Mannose><Mediating><Membrane Fusion><Mentorship><Metabolic Glycosylation><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Sieve Chromatography><Molecular Stereochemistry><Mutation><Pb element><Pharmaceutical Agent><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Phase><Polysaccharides><Process><Proteins><Receptor Protein><Research><Research Resources><Resources><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Risk><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Science><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Size Exclusion Chromatography><Solvents><Spanish flu><Spanish influenza><Specificity><Structure><Surface><Testing><Therapeutic><Therapeutic antibodies><Training><Treatment Efficacy><Universities><Vaccination><Vaccine Research><Vaccines><Variant><Variation><Viral><Viral Diseases><Viral Genome><Virion><Virus><Virus Diseases><Virus Particle><Virus-HIV><Work><Workshop><Writing><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><beta CoV><beta coronavirus><betaCoV><betacoronavirus><biophysical foundation><biophysical principles><biophysical sciences><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><block viral entry><carbohydrate binding protein><career><career development><combat><conference><conformation><conformational state><convalescent plasma><convention><corona virus><corona virus disease 2019><corona virus disease 2019 vaccine><corona virus emergence><coronavirus S protein><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 infection><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus spike glycoprotein><design><designing><developmental><emergency use authorization><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experiment><experimental research><experimental study><fight against><genome mutation><glycosylation><gp-120><gp-120 Antigen><hCoV19><health care personnel><health care worker><health provider><health workforce><healthcare personnel><heavy metal Pb><heavy metal lead><human CoV><human corona virus><human coronavirus><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibit viral entry><inhibitor><instrumentation><intervention efficacy><interventional strategy><knowledge of results><light scattering><medical personnel><member><model of animal><model organism><nCoV><nCoV2><nano-molar><nanomolar><neutralizing antibody><new CoV><new corona virus><new coronavirus><novel><novel CoV><novel corona virus><novel coronavirus><pandemic><pandemic disease><prevent><preventing><receptor><receptor binding><receptor bound><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><skills><structural biology><summit><symposia><symposium><therapeutic efficacy><therapy efficacy><treatment provider><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><variants of concern><viral entry blocker><viral entry inhibitor><viral infection><virology><virus genome><virus infection><virus-induced disease><weapons><β CoV><β coronavirus><βCoV>